IBD Science for Patients

When you live with Crohn’s disease, understanding what drives inflammation inside your bowel is a key part of your healthcare journey. While genetics and immune system responses play major roles, scientists have long suspected that specific “troublemaker” bacteria in the digestive tract act as active triggers. One particular bacterial offender is a sticky strain called adherent-invasive Escherichia coli (AIEC).

Unlike normal, harmless gut bacteria that float freely in intestinal fluid, AIEC bacteria cling tightly to the lining of your bowel, penetrate gut cells, and drive persistent, chronic inflammation.

Now, a clinical trial brings encouraging news. Researchers have demonstrated that a single dose of faecal microbiota transplantation (FMT) delivered during a colonoscopy can successfully clear these sticky bacteria directly from the gut lining.

Behind the Technology: Sampling the Gut Wall

To understand how this treatment works, it helps to break down the medical terminology and diagnostic tools used in the trial:

• Adherent-Invasive Escherichia coli (AIEC): A specific, aggressive subtype of E. coli bacteria. It is described as “adherent” because it attaches firmly to intestinal mucosal cells, and “invasive” because it sneaks inside gut wall tissues to evade your body’s immune system.
• Faecal Microbiota Transplantation (FMT): A medical procedure where healthy, thoroughly screened donor gut bacteria are transferred directly into a patient’s colon during a routine colonoscopy. The goal is to reset an unhealthy microbial community and restore balance.
• Ileal Mucosal Biopsy vs Stool Tests: Most microbiome studies rely solely on stool samples. However, stool tests can miss bacteria clinging directly to the bowel wall. In this study, doctors took tiny tissue biopsies from the ileum (the final section of the small intestine where Crohn’s inflammation often clusters).
• Shotgun Metagenomic and 16S rRNA Sequencing: Advanced DNA-sequencing technologies used to analyse the biopsies. These high-tech tools read the genetic codes of all microbes living directly on the mucosal tissue, providing a microscopic map of the gut lining.
• Serum Anti-E. coli Antibodies (AEcAb): A blood biomarker test that checks whether your immune system has developed specific antibodies against E. coli proteins, flagging patients who are likely carrying AIEC bacteria.

Study Scale and the 12-Week Timeline

To evaluate whether healthy donor microbes could clear AIEC from the intestinal wall, researchers conducted an open-label pilot clinical trial.

The study enrolled 30 adult patients with Crohn’s disease who tested positive for serum anti-E. coli antibodies. Each participant received a single FMT infusion during a colonoscopy from one of two carefully screened healthy donors. The research team collected blood, stool, and ileal tissue biopsies at baseline and tracked participants over a 12-week monitoring period.

Among the cohort, 8 evaluable patients had confirmed AIEC colonisation living directly on their ileal mucosal tissue at the start of the trial.

Key Discoveries: Complete Decolonisation on the Intestinal Lining

The trial yielded significant insights into how healthy donor microbes interact with the gut wall:

1. 100 Per Cent Decolonisation in Carriers: Following a single FMT infusion, AIEC was no longer detectable on the gut lining in all 8 evaluable baseline-positive patients (a 100 per cent decolonisation rate on the intestinal tissue).
2. Boosting Microbial Diversity: After receiving the transplant, patients experienced a significant increase in alpha diversity (the variety and abundance of beneficial bacterial species living on the ileal gut wall, p = 0.023).
3. Dropping Inflammatory Markers: The study revealed that as mucosal bacterial diversity increased following FMT, patients experienced corresponding drops in faecal calprotectin (a key protein measured in stool samples that flags active gut inflammation).
4. Safety Profile: No FMT-related serious adverse events occurred over the 12-week study, confirming that the procedure was well tolerated by participants.

Why This Matters to You as a Patient

If you are managing Crohn’s disease, this research marks an exciting shift toward precision medicine for your digestive health:

1. Proof That Specific Bad Bacteria Can Be Cleared: This study proves that doctors can target and clear specific “invader” bacteria living on your gut wall, rather than relying solely on drugs that suppress your entire immune system.
2. Shifting Focus to Tissue Healing: Knowing that diagnostic tests can check the bacteria clinging directly to your intestinal lining means future treatments will focus on restoring healthy tissue where inflammation actually starts.
3. A Hopeful Building Block for Future Care: While a small pilot study does not mean FMT is an immediate, routine cure for Crohn’s disease, it proves that modifying your gut microbiome can clear harmful bacterial strains. When combined with whole-food nutritional strategies or targeted biologic therapies, microbiome-targeted interventions offer a hopeful, proactive frontier for your healthcare.

By targeting specific bacterial drivers of inflammation, science is paving the way for personalised therapies that restore lasting balance to your gut wall.

---